3T Biosciences Names Behzad Kharabi as New Chief Medical Officer
3T Biosciences Appoints Behzad Kharabi as Chief Medical Officer
San francisco, CA – 3T Biosciences, a biotech company pioneering a novel approach to precision immunotherapy, has announced the appointment of Behzad Kharabi, MD, as its new Chief Medical officer. Dr. Kharabi brings a wealth of experience in clinical development adn immunotherapy leadership to the role, positioning 3T Biosciences for continued growth and innovation in the fight against cancer.
Prior to joining 3T Biosciences, Dr. Kharabi served as Chief Medical Officer at T-Knife Therapeutics, where he oversaw the clinical strategy and execution for the company’s T-cell receptor (TCR) therapies. His expertise in navigating the complexities of clinical trials and regulatory pathways will be invaluable as 3T Biosciences advances its own pipeline of personalized cancer treatments. https://www.3tbiosciences.com/
3T Biosciences is focused on developing individualized cancer therapies based on a deep understanding of the tumor microenvironment and the patient’s unique immune response. The company’s proprietary platform,utilizing its novel approach to T cell receptor (TCR) discovery,aims to identify and engineer T cells that specifically target neoantigens – unique mutations found in each patient’s tumor. This personalized approach holds the potential to overcome the limitations of conventional immunotherapies, which often fail due to tumor heterogeneity and immune evasion.
“We are thrilled to welcome Dr. Kharabi to the 3T Biosciences team,” said sukhdeep Gill, CEO of 3T Biosciences. “His proven track record of success in clinical development, particularly in the field of T-cell therapies, will be instrumental as we move our programs forward and strive to deliver transformative treatments to patients with cancer.”
The appointment of a seasoned medical leader like Dr. Kharabi underscores the growing momentum within the precision immunotherapy space. Immunotherapy has revolutionized cancer treatment in recent years, but a critically important portion of patients do not respond to existing therapies. Companies like 3T Biosciences are at the forefront of efforts to personalize these treatments, tailoring them to the specific characteristics of each patient’s tumor and immune system.
Dr. Kharabi’s experience extends beyond T-Knife Therapeutics. He has held leadership positions at several other biotechnology companies and has been involved in the development of multiple oncology drugs. his background includes a strong focus on translational research, bridging the gap between laboratory discoveries and clinical submission. This expertise will be crucial in guiding 3T Biosciences’ efforts to translate its innovative platform into meaningful clinical benefits for patients.
The biotech industry continues to experience a dynamic period of growth and change, with frequent leadership transitions as companies seek to bolster their teams and accelerate their pipelines. Staying abreast of these changes is vital for those following the industry, as these appointments often signal strategic shifts and future directions. https://www.statnews.com/pharmalot/2026/01/23/pharma-biotech-jobs-teva-novartis-novo-lilly/
While the demands of a Chief Medical Officer role are significant, a healthy work-life balance remains essential for effective leadership and sustained innovation. the industry recognizes the importance of fostering a supportive environment that allows leaders to thrive both professionally and personally.